Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
Clinical trial NCT07185256 · RECRUITING
Trial details
- NCT number
- NCT07185256
- Sponsor
- Opus Genetics, Inc
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-25
- Primary completion
- 2030-08-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.